百奥泰生物

Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company based in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, ophthalmic, and other serious diseases, as well as biosimilars of existing, branded biologics. As a leader in next-generation antibody drug development, the company has advanced multiple candidates into late-stage development, including several approved products: Gelestra® (Adalimumab), Pubeschi® (Bevacizumab), and Shirlie® (Tocilizumab) in China, and TOFIDENCETM (Tocilizumab) and Avzivi® (Bevacizumab) in the U.S. The company currently has over 20 promising candidates in various stages of clinical trials, with a focus on immuno-oncology in the post-PD-1 era and targeted therapies such as Antibody Drug Conjugates (ADCs). For more information, please visit our website or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).